Director at Recursion Pharmaceuticals (NASDAQ: RXRX) sells 40,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson reported multiple share transactions. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.46 each under a Rule 10b5-1 trading plan. Separately, 27,265 Class A shares were disposed of to cover tax withholding on restricted stock units.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 40,000 shares ($138,400)
Net Sell
13 txns
Insider
Gibson Christopher
Role
Director
Sold
40,000 shs ($138K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 40,000 | $0.00 | -- |
| Sale | Class A Common Stock | 40,000 | $3.46 | $138K |
| Tax Withholding | Class A Common Stock | 27,265 | $3.49 | $95K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Class B Common Stock — 4,543,334 shares (Direct);
Class A Common Stock — 946,556 shares (Direct);
Class B Common Stock — 0 shares (Indirect, by LAHWRAN-3 LLC);
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transactions did Christopher Gibson report at RXRX?
Christopher Gibson reported several transactions involving Recursion Pharmaceuticals (RXRX) stock. He converted 40,000 Class B shares into Class A shares, sold 40,000 Class A shares at $3.46 each, and disposed of 27,265 Class A shares to satisfy tax withholding on restricted stock units.
What does the derivative conversion in the RXRX Form 4 mean?
The Form 4 shows a conversion of 40,000 Class B Common shares into 40,000 Class A Common shares. Each Class B share is convertible into one Class A share at the holder’s option and has no expiration date, as described in the filing footnotes.